| PMID |
17853944 ( ![]() ![]() ![]() ) |
|---|---|
| Title | Redox modifier genes in amyotrophic lateral sclerosis in mice. |
| Abstract | Amyotrophic lateral sclerosis (ALS), one of the most common adult-onset neurodegenerative diseases, has no known cure. Enhanced redox stress and inflammation have been associated with the pathoprogression of ALS through a poorly defined mechanism. Here we determined that dysregulated redox stress in ALS mice caused by NADPH oxidases Nox1 and Nox2 significantly influenced the progression of motor neuron disease caused by mutant SOD1(G93A) expression. Deletion of either Nox gene significantly slowed disease progression and improved survival. However, 50% survival rates were enhanced significantly more by Nox2 deletion than by Nox1 deletion. Interestingly, female ALS mice containing only 1 active X-linked Nox1 or Nox2 gene also had significantly delayed disease onset, but showed normal disease progression rates. Nox activity in spinal cords from Nox2 heterozygous female ALS mice was approximately 50% that of WT female ALS mice, suggesting that random X-inactivation was not influenced by Nox2 gene deletion. Hence, chimerism with respect to Nox-expressing cells in the spinal cord significantly delayed onset of motor neuron disease in ALS. These studies define what we believe to be new modifier gene targets for treatment of ALS. University of Iowa, Iowa City, Iowa, USA. |
NOTE: Color highlight is limited to the abstract and SciMiner text-mining mode. If you see much more identified targets below from "Targets by SciMiner Summary" and "Targets by SciMiner Full list", they may have been identified from the full text.
Targets by SciMiner Summary
| HUGO ID | Symbol | Target Name | #Occur | ActualStr |
|---|---|---|---|---|
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | 129 | Nox2 | NOX2 | gp91phox | |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | 106 | superoxide dismutase 1 | SOD1 | hSOD1 | SOD | |
| 7889 | NOX1 | NADPH oxidase 1 | 38 | NOX1 | nadph oxidase 1 | Nox1-deficient | |
| 14874 | NOX5 | NADPH oxidase, EF-hand calcium binding domain 5 | 5 | Nox5 | nadph oxidase | |
| 6001 | IL2 | interleukin 2 | 3 | mIL2 | |
| 13273 | DUOX2 | dual oxidase 2 | 2 | DUOX2 | Duox2 | |
| 6149 | ITGAM | integrin, alpha M (complement component 3 receptor 3 subunit) | 2 | CD11b | |
| 7661 | NCF2 | neutrophil cytosolic factor 2 (65kDa, chronic granulomatous disease, autosomal 2) | 1 | chronic granulomatous disease | |
| 9801 | RAC1 | ras-related C3 botulinum toxin substrate 1 (rho family, small GTP binding protein Rac1) | 1 | Rac1 | |
| 7890 | NOX3 | NADPH oxidase 3 | 1 | Nox3 | |
| 2961 | DYNC1H1 | dynein, cytoplasmic 1, heavy chain 1 | 1 | p22 | |
| 7891 | NOX4 | NADPH oxidase 4 | 1 | Nox4 | |
| 2577 | CYBA | cytochrome b-245, alpha polypeptide | 1 | p22 phox | |
| 3062 | DUOX1 | dual oxidase 1 | 1 | Duox1 | |
Targets by SciMiner Full list
| HUGO ID | Symbol | Name | ActualStr | Score | FlankingText |
|---|---|---|---|---|---|
| 7889 | NOX1 | NADPH oxidase 1 | Nox1 | 4.2 | dysregulated redox stress in ALS mice caused by NADPH oxidases Nox1 and Nox2 significantly influenced the progression of motor neuron disease |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | NOX2 | 7.1 | dysregulated redox stress in ALS mice caused by NADPH oxidases Nox1 and Nox2 significantly influenced the progression of motor neuron disease |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | stress in ALS mice caused by NADPH oxidases Nox1 and Nox2 significantly influenced the progression of motor neuron disease caused by |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | influenced the progression of motor neuron disease caused by mutant SOD1 G93A expression |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | However 50% survival rates were enhanced significantly more by Nox2 deletion than by Nox1 deletion |
| 7889 | NOX1 | NADPH oxidase 1 | Nox1 | 4.2 | rates were enhanced significantly more by Nox2 deletion than by Nox1 deletion |
| 7889 | NOX1 | NADPH oxidase 1 | Nox1 | 4.2 | Interestingly female ALS mice containing only 1 active X-linked Nox1 or Nox2 gene also had significantly delayed disease onset but |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | female ALS mice containing only 1 active X-linked Nox1 or Nox2 gene also had significantly delayed disease onset but showed normal |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | Nox activity in spinal cords from Nox2 heterozygous female ALS mice was approximately 50% that of WT |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | ALS mice suggesting that random X-inactivation was not influenced by Nox2 gene deletion |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | can be caused by dominant mutations in superoxide dismutase-1 (SOD1) SOD1 ( 1 |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | Transgenic mice overexpressing a mutant form of SOD1 found in ALS patients (SOD1 SOD1 G93A develop motor neuron |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | a mutant form of SOD1 found in ALS patients (SOD1 SOD1 G93A develop motor neuron disease similar to that seen clinically |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | Recent studies using conditional reduction of mutant SOD1 in either motor neurons or glia of mice have suggested |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | transplants or chimeric animals other studies have demonstrated that mutant SOD1 expression in microglia leads to neuronal toxicity ( 5 and |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | toxicity ( 5 and that non-neuronal cells lacking the mutant SOD1 protein can protect from disease ( 6 |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | Indeed recent studies have shown that SOD1 G93A ALS transgenic mice produce elevated levels of Nox2 gp91phox |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | that SOD1 G93A ALS transgenic mice produce elevated levels of Nox2 gp91phox and superoxide in spinal cord microglia ( 8 |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | gp91phox | 2.0 | SOD1 G93A ALS transgenic mice produce elevated levels of Nox2 gp91phox and superoxide in spinal cord microglia ( 8 |
| 7889 | NOX1 | NADPH oxidase 1 | Nox1 | 4.2 | Seven known NADPH oxidases (Nox1, Nox1 Nox2 Nox3 Nox4 Nox5 Duox1 and Duox2 are thought to |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | Seven known NADPH oxidases (Nox1, Nox1 Nox2 Nox3 Nox4 Nox5 Duox1 and Duox2 are thought to play |
| 7890 | NOX3 | NADPH oxidase 3 | Nox3 | 0.9 | Seven known NADPH oxidases (Nox1, Nox1 Nox2 Nox3 Nox4 Nox5 Duox1 and Duox2 are thought to play important |
| 7891 | NOX4 | NADPH oxidase 4 | Nox4 | 0.9 | Seven known NADPH oxidases (Nox1, Nox1 Nox2 Nox3 Nox4 Nox5 Duox1 and Duox2 are thought to play important roles |
| 14874 | NOX5 | NADPH oxidase, EF-hand calcium binding domain 5 | Nox5 | 0.9 | Seven known NADPH oxidases (Nox1, Nox1 Nox2 Nox3 Nox4 Nox5 Duox1 and Duox2 are thought to play important roles in |
| 3062 | DUOX1 | dual oxidase 1 | Duox1 | 0.3 | Seven known NADPH oxidases (Nox1, Nox1 Nox2 Nox3 Nox4 Nox5 Duox1 and Duox2 are thought to play important roles in redox-dependent |
| 13273 | DUOX2 | dual oxidase 2 | DUOX2 | 0.3 | Seven known NADPH oxidases (Nox1, Nox1 Nox2 Nox3 Nox4 Nox5 Duox1 and Duox2 are thought to play important roles in redox-dependent |
| 13273 | DUOX2 | dual oxidase 2 | Duox2 | 0.3 | NADPH oxidases (Nox1, Nox1 Nox2 Nox3 Nox4 Nox5 Duox1 and Duox2 are thought to play important roles in redox-dependent cell signaling |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | Although Nox2 expression increases in microglia of the spinal cord of SOD1 |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | Nox2 expression increases in microglia of the spinal cord of SOD1 G93A transgenic mice deletion of Nox2 on a C57BL/6J C57BL |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | the spinal cord of SOD1 G93A transgenic mice deletion of Nox2 on a C57BL/6J C57BL 6J inbred background of SOD1 G93A |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | of Nox2 on a C57BL/6J C57BL 6J inbred background of SOD1 G93A transgenic mice led to only a marginal increase in |
| 7889 | NOX1 | NADPH oxidase 1 | Nox1 | 4.2 | Nox1 and Nox2 are closely related homologs in the Nox gene |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | NOX2 | 7.1 | Nox1 and Nox2 are closely related homologs in the Nox gene |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | Nox1 and Nox2 are closely related homologs in the Nox gene family and |
| 9801 | RAC1 | ras-related C3 botulinum toxin substrate 1 (rho family, small GTP binding protein Rac1) | Rac1 | 0.0 | many of the same regulatory characteristics including a requirement for Rac1 and p22 phox coactivators ( 10 _amp_#x02013 12 |
| 2961 | DYNC1H1 | dynein, cytoplasmic 1, heavy chain 1 | p22 | 0.0 | the same regulatory characteristics including a requirement for Rac1 and p22 phox coactivators ( 10 _amp_#x02013 12 |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | To this end we performed studies comparing the contribution of Nox2 or Nox1 deletion on disease progression in mixed hybrid SOD1 |
| 7889 | NOX1 | NADPH oxidase 1 | Nox1 | 4.2 | end we performed studies comparing the contribution of Nox2 or Nox1 deletion on disease progression in mixed hybrid SOD1 G93A ALS |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | Nox2 or Nox1 deletion on disease progression in mixed hybrid SOD1 G93A ALS mice |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | X_amp_#x02013 and KO Nox X_amp_#x02013;/X_amp_#x02013; X_amp_#x02013 X_amp_#x02013 mice on the SOD1 G93A transgenic background using siblings from F2 generations |
| 7889 | NOX1 | NADPH oxidase 1 | Nox1 | 4.2 | show that disrupting either of these NADPH oxidase genes ( Nox1 or Nox2 significantly delayed the progression of motor neuron disease |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | disrupting either of these NADPH oxidase genes ( Nox1 or Nox2 significantly delayed the progression of motor neuron disease in a |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | significantly delayed the progression of motor neuron disease in a SOD1 G93A transgenic mouse model of ALS |
| 7889 | NOX1 | NADPH oxidase 1 | Nox1 | 4.2 | female ALS mice lacking a single copy of the X-chromosomal Nox1 or Nox2 genes also exhibited significantly increased survival rates |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | mice lacking a single copy of the X-chromosomal Nox1 or Nox2 genes also exhibited significantly increased survival rates |
| 7889 | NOX1 | NADPH oxidase 1 | Nox1 | 4.2 | in the setting of random X-inactivation a 50% reduction in Nox1 - or Nox2 -expressing cells has a substantial therapeutic benefit |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | of random X-inactivation a 50% reduction in Nox1 - or Nox2 -expressing cells has a substantial therapeutic benefit in ALS mice |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | (a) a Transgenic mice overexpressing the human SOD1 G93A mutant ( 22 were used as a model of |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | used as a model of ALS strain name B6SJL-Tg( B6SJL-Tg SOD1 G93A )1Gur/J; 1Gur J stock no 002726 The Jackson Laboratory |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | (b) b Nox2 gp91phox KO mice ( 23 were also obtained from The |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | gp91phox | 2.0 | (b) b Nox2 gp91phox KO mice ( 23 were also obtained from The Jackson |
| 7889 | NOX1 | NADPH oxidase 1 | Nox1 | 4.2 | (c) c Nox1 KO mice ( 24 were a kind gift from K.H |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | The generation of SOD1 G93A transgenic mice on the Nox2 -KO or Nox1 -KO |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | The generation of SOD1 G93A transgenic mice on the Nox2 -KO or Nox1 -KO backgrounds were achieved using the following |
| 7889 | NOX1 | NADPH oxidase 1 | Nox1 | 4.2 | of SOD1 G93A transgenic mice on the Nox2 -KO or Nox1 -KO backgrounds were achieved using the following breeding scheme |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | Because both Nox2 and Nox1 genes are on the X chromosome 2 rounds |
| 7889 | NOX1 | NADPH oxidase 1 | NOX1 | 4.2 | Because both Nox2 and Nox1 genes are on the X chromosome 2 rounds |
| 7889 | NOX1 | NADPH oxidase 1 | Nox1 | 4.2 | Because both Nox2 and Nox1 genes are on the X chromosome 2 rounds of breeding |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | Hemizygous SOD1 G93A transgenic males were bred to Nox2 _amp_#x02013;/_amp_#x02013; _amp_#x02013 _amp_#x02013 |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | Hemizygous SOD1 G93A transgenic males were bred to Nox2 _amp_#x02013;/_amp_#x02013; _amp_#x02013 _amp_#x02013 or Nox1 _amp_#x02013;/_amp_#x02013; _amp_#x02013 _amp_#x02013 females |
| 7889 | NOX1 | NADPH oxidase 1 | Nox1 | 4.2 | transgenic males were bred to Nox2 _amp_#x02013;/_amp_#x02013; _amp_#x02013 _amp_#x02013 or Nox1 _amp_#x02013;/_amp_#x02013; _amp_#x02013 _amp_#x02013 females |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | females were used for the next round of breeding against SOD1 G93A hemizygous Nox -KO males (i.e., i.e. Nox2 +/_amp_#x02013; _amp_#x02013 |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | breeding against SOD1 G93A hemizygous Nox -KO males (i.e., i.e. Nox2 +/_amp_#x02013; _amp_#x02013 _amp_#x000d7 SOD1 G93A / Nox2 _amp_#x02013;/Y _amp_#x02013 Y |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | hemizygous Nox -KO males (i.e., i.e. Nox2 +/_amp_#x02013; _amp_#x02013 _amp_#x000d7 SOD1 G93A / Nox2 _amp_#x02013;/Y _amp_#x02013 Y or Nox1 +/_amp_#x02013; _amp_#x02013 |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | males (i.e., i.e. Nox2 +/_amp_#x02013; _amp_#x02013 _amp_#x000d7 SOD1 G93A / Nox2 _amp_#x02013;/Y _amp_#x02013 Y or Nox1 +/_amp_#x02013; _amp_#x02013 _amp_#x000d7 SOD1 G93A |
| 7889 | NOX1 | NADPH oxidase 1 | Nox1 | 4.2 | _amp_#x02013 _amp_#x000d7 SOD1 G93A / Nox2 _amp_#x02013;/Y _amp_#x02013 Y or Nox1 +/_amp_#x02013; _amp_#x02013 _amp_#x000d7 SOD1 G93A / Nox1 _amp_#x02013;/Y _amp_#x02013 Y |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | / Nox2 _amp_#x02013;/Y _amp_#x02013 Y or Nox1 +/_amp_#x02013; _amp_#x02013 _amp_#x000d7 SOD1 G93A / Nox1 _amp_#x02013;/Y _amp_#x02013 Y to give rise to |
| 7889 | NOX1 | NADPH oxidase 1 | Nox1 | 4.2 | _amp_#x02013 Y or Nox1 +/_amp_#x02013; _amp_#x02013 _amp_#x000d7 SOD1 G93A / Nox1 _amp_#x02013;/Y _amp_#x02013 Y to give rise to mixed litters containing |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | (male male only genotypes either lacking or hemizygous for the SOD1 G93A transgene |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | Similarly Nox -HET females were also bred against SOD1 G93A hemizygous Nox -WT males (i.e., i.e. Nox2 +/_amp_#x02013; _amp_#x02013 |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | bred against SOD1 G93A hemizygous Nox -WT males (i.e., i.e. Nox2 +/_amp_#x02013; _amp_#x02013 _amp_#x000d7 SOD1 G93A / Nox2 +/Y Y or |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | hemizygous Nox -WT males (i.e., i.e. Nox2 +/_amp_#x02013; _amp_#x02013 _amp_#x000d7 SOD1 G93A / Nox2 +/Y Y or Nox1 +/_amp_#x02013; _amp_#x02013 _amp_#x000d7 |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | males (i.e., i.e. Nox2 +/_amp_#x02013; _amp_#x02013 _amp_#x000d7 SOD1 G93A / Nox2 +/Y Y or Nox1 +/_amp_#x02013; _amp_#x02013 _amp_#x000d7 SOD1 G93A / |
| 7889 | NOX1 | NADPH oxidase 1 | Nox1 | 4.2 | +/_amp_#x02013; _amp_#x02013 _amp_#x000d7 SOD1 G93A / Nox2 +/Y Y or Nox1 +/_amp_#x02013; _amp_#x02013 _amp_#x000d7 SOD1 G93A / Nox1 +/Y Y to |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | G93A / Nox2 +/Y Y or Nox1 +/_amp_#x02013; _amp_#x02013 _amp_#x000d7 SOD1 G93A / Nox1 +/Y Y to give rise to mixed |
| 7889 | NOX1 | NADPH oxidase 1 | Nox1 | 4.2 | +/Y Y or Nox1 +/_amp_#x02013; _amp_#x02013 _amp_#x000d7 SOD1 G93A / Nox1 +/Y Y to give rise to mixed litters containing Nox |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | male and female genotypes either lacking or hemizygous for the SOD1 G93A transgene |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | Genotyping for Nox2 and SOD1 G93A mice was performed by standard PCR protocols |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | Genotyping for Nox2 and SOD1 G93A mice was performed by standard PCR protocols using primer |
| 7889 | NOX1 | NADPH oxidase 1 | Nox1 | 4.2 | Nox1 PCR genotypes were performed as previously described ( 24 |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | Methods Real-time quantitative PCR determination of SOD1 G93A transgene copy number |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | hSOD1 | 2.2 | in threshold cycle (_amp_#x00394;CT) _amp_#x00394 CT between the transgene ( hSOD1 and a reference gene ( mIL2 following a previously published |
| 6001 | IL2 | interleukin 2 | mIL2 | 1.1 | between the transgene ( hSOD1 and a reference gene ( mIL2 following a previously published protocol ( 25 |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | hSOD1 | 2.2 | The following primers were used for the transgene hSOD1 forward 5_amp_#x02032 -CATCAGCCCTAATCCATCTGA-3_amp_#x02032 reverse 5_amp_#x02032 -CGCGACTAACAATCAAAGTGA-3_amp_#x02032 |
| 6001 | IL2 | interleukin 2 | mIL2 | 1.1 | The following primers were used for the reference gene mIL2 forward 5_amp_#x02032 -CTAGGCCACAGAATTGAAAGATCT-3_amp_#x02032 reverse 5_amp_#x02032 -GTAGGTGGAAATTCTAGCATCATCC-3_amp_#x02032 |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | hSOD1 | 2.2 | The final concentration of the primers for hSOD1 and mIL2 were 0.4 and 0.5 _amp_#x003bc M respectively |
| 6001 | IL2 | interleukin 2 | mIL2 | 1.1 | The final concentration of the primers for hSOD1 and mIL2 were 0.4 and 0.5 _amp_#x003bc M respectively |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | _amp_#x00394 CT was calculated as the difference between the human SOD1 CT and the mouse IL2 CT for all mice in |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | and the mouse IL2 CT for all mice in the Nox2 F2 generation |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | 24 and _amp_#x00394 CT (6.967) 6.967 of the B6SJL-TgN( B6SJL-TgN SOD1 G93A 1Gur as known values ( 26 |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | B6SJL-Tg( B6SJL-Tg SOD1 G93A )1Gur/J 1Gur J mice hemizygous for a highly expressed |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | )1Gur/J 1Gur J mice hemizygous for a highly expressed mutant SOD1 G93A transgene develop disease onset at approximately 110 days of |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | our hands 50% survival was 123 days for B6SJL-Tg( B6SJL-Tg SOD1 G93A )1Gur/J 1Gur J males ( n = 30 and |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | the study because their presymptomatic weight exceeded 40 g 2 Nox2 -WT 1 Nox2 -HET and 1 Nox2 -KO |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | their presymptomatic weight exceeded 40 g 2 Nox2 -WT 1 Nox2 -HET and 1 Nox2 -KO |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | 40 g 2 Nox2 -WT 1 Nox2 -HET and 1 Nox2 -KO |
| 7889 | NOX1 | NADPH oxidase 1 | Nox1 | 4.2 | None of the mice on the Nox1 -KO background failed the weight criteria |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | Nox2 -KO mice also hemizygous for the SOD1 G93A transgene were |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | Nox2 -KO mice also hemizygous for the SOD1 G93A transgene were susceptible to superficial eye infections |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | that antibiotic treatment did not alter the course of disease SOD1 G93A / Nox2 -WT mice were put on antibiotic water |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | did not alter the course of disease SOD1 G93A / Nox2 -WT mice were put on antibiotic water at 90 days |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | Eye infection in Nox2 -HET females hemizygous for the SOD1 G93A transgene was only |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | Eye infection in Nox2 -HET females hemizygous for the SOD1 G93A transgene was only observed in 1 of the 8 |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | of the 8 females analyzed and was never observed in Nox2 -KO mice lacking the SOD1 G93A transgene |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | and was never observed in Nox2 -KO mice lacking the SOD1 G93A transgene |
| 6149 | ITGAM | integrin, alpha M (complement component 3 receptor 3 subunit) | CD11b | 1.0 | Activated microglia were immunostained using a CD11b antibody from AbD Serotec Inc at a 1 100 dilution |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | spinal cord lysates made from the lumbar region of 120-day-old SOD1 G93A Nox2 -WT SOD1 G93A Nox2 -KO and nontransgenic mice |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | lysates made from the lumbar region of 120-day-old SOD1 G93A Nox2 -WT SOD1 G93A Nox2 -KO and nontransgenic mice |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | from the lumbar region of 120-day-old SOD1 G93A Nox2 -WT SOD1 G93A Nox2 -KO and nontransgenic mice |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | lumbar region of 120-day-old SOD1 G93A Nox2 -WT SOD1 G93A Nox2 -KO and nontransgenic mice |
| 7889 | NOX1 | NADPH oxidase 1 | Nox1 | 4.2 | Results and Discussion Gene deletion of Nox1 or Nox2 increases survival and slows disease progression in SOD1 |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | Results and Discussion Gene deletion of Nox1 or Nox2 increases survival and slows disease progression in SOD1 G93A transgenic |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | Nox1 or Nox2 increases survival and slows disease progression in SOD1 G93A transgenic mice |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | 2 potential Nox genes responsible for ROS generation in hemizygous SOD1 G93A transgenic mice and their affect on the progression of |
| 7889 | NOX1 | NADPH oxidase 1 | Nox1 | 4.2 | We bred female Nox1 -KO and Nox2 -KO mice to hemizygous male SOD1 G93A |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | We bred female Nox1 -KO and Nox2 -KO mice to hemizygous male SOD1 G93A ALS mice (Supplemental |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | female Nox1 -KO and Nox2 -KO mice to hemizygous male SOD1 G93A ALS mice (Supplemental Supplemental Figures 1 and 2 supplemental |
| 7889 | NOX1 | NADPH oxidase 1 | Nox1 | 4.2 | possible genotypes in both male and female siblings because both Nox1 and Nox2 are on the X chromosome |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | NOX2 | 7.1 | possible genotypes in both male and female siblings because both Nox1 and Nox2 are on the X chromosome |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | in both male and female siblings because both Nox1 and Nox2 are on the X chromosome |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | Mutant SOD1 transgene copy number was also stable throughout the F2 generations |
| 7889 | NOX1 | NADPH oxidase 1 | Nox1 | 4.2 | The Nox1 and Nox2 mice were both maintained on the C57BL/6 C57BL |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | NOX2 | 7.1 | The Nox1 and Nox2 mice were both maintained on the C57BL/6 C57BL |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | The Nox1 and Nox2 mice were both maintained on the C57BL/6 C57BL 6 background |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | maintained on the C57BL/6 C57BL 6 background however only the Nox2 mice were inbred to greater than 13 generations ( Nox1 |
| 7889 | NOX1 | NADPH oxidase 1 | Nox1 | 4.2 | Nox2 mice were inbred to greater than 13 generations ( Nox1 KO mice were backcrossed about 7 generations onto the C57BL/6 |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | Unlike a previous study evaluating deletion of the Nox2 gene in SOD1 G93A C57BL/6J C57BL 6J inbred transgenic mice |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | a previous study evaluating deletion of the Nox2 gene in SOD1 G93A C57BL/6J C57BL 6J inbred transgenic mice ( 8 our |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | C57BL 6J inbred transgenic mice ( 8 our study used SOD1 G93A B6SJL mice on a mixed hybrid background (F1 F1 |
| 7889 | NOX1 | NADPH oxidase 1 | Nox1 | 4.2 | Homozygous deletion of either Nox1 or Nox2 significantly delayed the death of hemizygous SOD1 G93A |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | Homozygous deletion of either Nox1 or Nox2 significantly delayed the death of hemizygous SOD1 G93A ALS mice |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | either Nox1 or Nox2 significantly delayed the death of hemizygous SOD1 G93A ALS mice (Figure Figure 1 A |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | Nox2 gene deletion had the greatest impact on survival in both |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | impact on survival in both male and female mice ( Nox2 -WT 132 days Nox2 -KO 229 days and also led |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | both male and female mice ( Nox2 -WT 132 days Nox2 -KO 229 days and also led to a 4-fold increase |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | The finding of an increased survival index in Nox2 -KO SOD1 G93A transgenic mice is significant because to our |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | The finding of an increased survival index in Nox2 -KO SOD1 G93A transgenic mice is significant because to our knowledge no |
| 7889 | NOX1 | NADPH oxidase 1 | Nox1-deficient | 1.9 | Nox1-deficient mice gave rise to a much smaller but still significant |
| 7889 | NOX1 | NADPH oxidase 1 | Nox1 | 4.2 | but still significant protective effect in terms of survival ( Nox1 -WT 129 days Nox1 -KO 162 days but not survival |
| 7889 | NOX1 | NADPH oxidase 1 | Nox1 | 4.2 | effect in terms of survival ( Nox1 -WT 129 days Nox1 -KO 162 days but not survival index (Figure Figure 1 |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | Given the significant 97-day increase in survival of Nox2 -KO SOD1 G93A B6SJL mice in our study compared with |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | Given the significant 97-day increase in survival of Nox2 -KO SOD1 G93A B6SJL mice in our study compared with the 13-day |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | with the 13-day increase observed in a previous study using Nox2 -KO SOD1 G93A congenic C57BL/6J C57BL 6J mice ( 8 |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | 13-day increase observed in a previous study using Nox2 -KO SOD1 G93A congenic C57BL/6J C57BL 6J mice ( 8 we investigated |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | congenic C57BL/6J C57BL 6J mice ( 8 we investigated the Nox2 dependence of several disease-associated phenotypes at the cellular level |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | Enhanced survival of ALS Nox2 -KO mice correlated with higher motor neuron counts in the |
| 6149 | ITGAM | integrin, alpha M (complement component 3 receptor 3 subunit) | CD11b | 1.0 | 120 days and reduced expression of the activated microglial marker CD11b (Figure Figure 2 |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | Deletion of Nox2 also resulted in reduced redox stress in spinal cords of |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | These findings were similar to those observed in the previous Nox2 -KO SOD1 G93A congenic C57BL/6J C57BL 6J study ( 8 |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | were similar to those observed in the previous Nox2 -KO SOD1 G93A congenic C57BL/6J C57BL 6J study ( 8 |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | death (Figure Figure 1 D were both significantly reduced in Nox2 -KO SOD1 G93A mice compared with Nox2 -WT SOD1 G93A |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | Figure 1 D were both significantly reduced in Nox2 -KO SOD1 G93A mice compared with Nox2 -WT SOD1 G93A mice |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | significantly reduced in Nox2 -KO SOD1 G93A mice compared with Nox2 -WT SOD1 G93A mice |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | in Nox2 -KO SOD1 G93A mice compared with Nox2 -WT SOD1 G93A mice |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | finding of decreased motor neuron disease in male and female Nox2 -KO ALS mice (Figure Figure 3 B_amp_#x02013 D |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | To determine whether Nox2 deficiency protected SOD1 G93A mice from muscle atrophy the weight |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | To determine whether Nox2 deficiency protected SOD1 G93A mice from muscle atrophy the weight fiber area and |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | At 100 days Nox2 -KO SOD1 G93A mice demonstrated significant protection from loss in |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | At 100 days Nox2 -KO SOD1 G93A mice demonstrated significant protection from loss in hind-limb muscle |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | significant protection from loss in hind-limb muscle mass compared with Nox2 -WT SOD1 G93A mice (Supplemental Supplemental Figure 5 A and |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | from loss in hind-limb muscle mass compared with Nox2 -WT SOD1 G93A mice (Supplemental Supplemental Figure 5 A and B |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | These differences in muscle mass between the Nox2 genotypes of SOD1 G93A mice correlated with changes in muscle |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | These differences in muscle mass between the Nox2 genotypes of SOD1 G93A mice correlated with changes in muscle fiber area (Supplemental |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | Furthermore Nox2 -KO SOD1 G93A mice were indistinguishable from nontransgenic littermates for |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | Furthermore Nox2 -KO SOD1 G93A mice were indistinguishable from nontransgenic littermates for both these |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | Breeding of hemizygous SOD1 G93A B6SJL mice onto the C57BL/6 C57BL 6 background has |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | to increase survival by approximately 13 to 14 days ( SOD1 G93A B6SJL hybrid mice 130.2 _amp_#x000b1 11.2 days SOD1 G93A |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | ( SOD1 G93A B6SJL hybrid mice 130.2 _amp_#x000b1 11.2 days SOD1 G93A C57BL/6 C57BL 6 congenic mice 143.6 _amp_#x000b1 7.5 days |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | analysis demonstrated increases in survival averaging 28 days when comparing SOD1 G93A B6SJL hybrid mice (128.9 128.9 _amp_#x000b1 9.1 days with |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | G93A B6SJL hybrid mice (128.9 128.9 _amp_#x000b1 9.1 days with SOD1 G93A C57BL/6J C57BL 6J congenic mice (157.1 157.1 _amp_#x000b1 9.3 |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | However the mean survival times for Nox -WT SOD1 G93A mice seen in our studies (129 129 and 132 |
| 7889 | NOX1 | NADPH oxidase 1 | Nox1 | 4.2 | seen in our studies (129 129 and 132 days for Nox1 and Nox2 backgrounds respectively were very similar to SOD1 G93A |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | NOX2 | 7.1 | seen in our studies (129 129 and 132 days for Nox1 and Nox2 backgrounds respectively were very similar to SOD1 G93A |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | our studies (129 129 and 132 days for Nox1 and Nox2 backgrounds respectively were very similar to SOD1 G93A B6SJL hybrid |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | for Nox1 and Nox2 backgrounds respectively were very similar to SOD1 G93A B6SJL hybrid mice in these previous reports |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | Because a previous study using inbred C57BL/6 C57BL 6 Nox2 -KO SOD1 G93A mice demonstrated much smaller increases in survival |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | a previous study using inbred C57BL/6 C57BL 6 Nox2 -KO SOD1 G93A mice demonstrated much smaller increases in survival ( 8 |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | in survival ( 8 compared with our mixed B6SJL background Nox2 -KO SOD1 G93A mice we hypothesize that multiple SJL-derived modifier |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | ( 8 compared with our mixed B6SJL background Nox2 -KO SOD1 G93A mice we hypothesize that multiple SJL-derived modifier genes likely |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | that multiple SJL-derived modifier genes likely act in concert with Nox2 deficiency to significantly enhance survival of SOD1 G93A mice |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | in concert with Nox2 deficiency to significantly enhance survival of SOD1 G93A mice |
| 7889 | NOX1 | NADPH oxidase 1 | Nox1 | 4.2 | degree of variability in survival among siblings for the various Nox1 and Nox2 SOD1 G93A genotypes in the F1 and F2 |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | NOX2 | 7.1 | degree of variability in survival among siblings for the various Nox1 and Nox2 SOD1 G93A genotypes in the F1 and F2 |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | variability in survival among siblings for the various Nox1 and Nox2 SOD1 G93A genotypes in the F1 and F2 generations (Supplemental |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | in survival among siblings for the various Nox1 and Nox2 SOD1 G93A genotypes in the F1 and F2 generations (Supplemental Supplemental |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | An embryonic stem cell_amp_#x02013 derived 129 segment linked to the Nox2 gene deletion near the telomere of the X chromosome likely |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | the telomere of the X chromosome likely segregates with the Nox2 mutant allele |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | to account for the increased survival seen in the B6SJL Nox2 -KO SOD1 G93A mice for 2 reasons |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | for the increased survival seen in the B6SJL Nox2 -KO SOD1 G93A mice for 2 reasons |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | First studies that have evaluated 129 modifier genes on the SOD1 G86R C57BL/6 C57BL 6 background suggest that they do not |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | Second this 129-derived segment linked to the targeted Nox2 allele on the telomere of the X chromosome would certainly |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | in the previous study that used inbred C57BL/6 C57BL 6 Nox2 -KO SOD1 G93A mice ( 8 |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | previous study that used inbred C57BL/6 C57BL 6 Nox2 -KO SOD1 G93A mice ( 8 |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | Because we used the same inbred C57BL/6 C57BL 6 Nox2 -KO mice for breeding yet observed widely divergent survival rates |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | mice for breeding yet observed widely divergent survival rates of Nox2 -KO SOD1 G93A mice it is unlikely this 129-linked segment |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | breeding yet observed widely divergent survival rates of Nox2 -KO SOD1 G93A mice it is unlikely this 129-linked segment can solely |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | Results and Discussion Female SOD1 G93A transgenic mice heterozygous for X-linked Nox genes have increased |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | Interestingly Nox2 -HET female ALS mice also demonstrated significant increases in survival |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | female ALS mice also demonstrated significant increases in survival ( Nox2 -WT 132 days Nox2 -HET 186 days Figure 1 A |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | demonstrated significant increases in survival ( Nox2 -WT 132 days Nox2 -HET 186 days Figure 1 A and Figure 3 A |
| 7889 | NOX1 | NADPH oxidase 1 | Nox1 | 4.2 | a limited but significant heterozygous effect on increased survival in Nox1 -HET female ALS mice (Figure Figure 1 A |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | substantiated the finding of decreased motor neuron disease in female Nox2 -HET ALS mice (Figure Figure 3 B_amp_#x02013 D |
| 7889 | NOX1 | NADPH oxidase 1 | Nox1 | 4.2 | Both Nox1 and Nox2 genes reside on the X chromosome |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | NOX2 | 7.1 | Both Nox1 and Nox2 genes reside on the X chromosome |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | Both Nox1 and Nox2 genes reside on the X chromosome |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | in female patients with X-linked chronic granulomatous disease caused by Nox2 gene mutations ( 17 |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | Given the significant protective effect seen in Nox2 -HET female mice we sought to determine how dosage of |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | -HET female mice we sought to determine how dosage of Nox2 activity in the spinal cord might influence disease progression in |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | end-stage disease Nox activity in the spinal cords of female Nox2 -HET SOD1 G93A mice fell between that of female Nox2 |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | Nox activity in the spinal cords of female Nox2 -HET SOD1 G93A mice fell between that of female Nox2 -KO and |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | Nox2 -HET SOD1 G93A mice fell between that of female Nox2 -KO and Nox2 -WT SOD1 G93A mice (Figure Figure 1 |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | G93A mice fell between that of female Nox2 -KO and Nox2 -WT SOD1 G93A mice (Figure Figure 1 C |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | fell between that of female Nox2 -KO and Nox2 -WT SOD1 G93A mice (Figure Figure 1 C |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | This suggests that X-inactivation likely occurs randomly in female Nox2 -HET SOD1 G93A mice with about 50% of the microglia |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | suggests that X-inactivation likely occurs randomly in female Nox2 -HET SOD1 G93A mice with about 50% of the microglia and neuronal |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | microglia and neuronal cell types predicted to be deficient for Nox2 function |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | These findings demonstrate that a 50% reduction of Nox2 activity in the spinal cord has a significant impact on |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | It is presently unclear why chimerism for Nox2 expression in the spinal cord significantly influences survival but not |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | significantly influences survival but not the survival index in female SOD1 G93A transgenic mice |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | reports generating chimeric mice composed of mixtures of normal and SOD1 mutant_amp_#x02013 expressing non-neuronal cells significantly attenuated toxicity associated with mutant-expressing |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | Given that Nox2 is highly expressed in microglia of SOD1 G93A transgenic mice |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | Given that Nox2 is highly expressed in microglia of SOD1 G93A transgenic mice ( 8 chimerism of Nox2 gene expression |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | microglia of SOD1 G93A transgenic mice ( 8 chimerism of Nox2 gene expression in microglia appears to influence disease progression |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | dictated by an altered redox-balance within cells expressing the mutant SOD1 through an as-yet undefined gain of function ( 2 3 |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | A recent study using conditional elimination of mutant SOD1 in neurons or glial cells has also demonstrated that these |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | demonstrating significantly enhanced survival in female ALS mice with chimeric Nox2 expression suggest that SOD1 G93A expression in microglia may directly |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | in female ALS mice with chimeric Nox2 expression suggest that SOD1 G93A expression in microglia may directly influence deleterious cell-autonomous function |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | expression in microglia may directly influence deleterious cell-autonomous function of Nox2 |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | Results and Discussion Nox2 deficiency leads to an enhanced predisposition to lethal eye infections |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | leads to an enhanced predisposition to lethal eye infections in SOD1 G93A transgenic mice |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | Notably in the Nox2 -KO SOD1 G93A transgenic background we observed a high frequency |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | Notably in the Nox2 -KO SOD1 G93A transgenic background we observed a high frequency of eye |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | These infections were never observed in Nox2 -KO littermates lacking the SOD1 G93A transgene |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | infections were never observed in Nox2 -KO littermates lacking the SOD1 G93A transgene |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | Importantly antibiotic treatment of control ALS mice on the WT Nox2 background did not alter either the progression of motor neuron |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | was rapid accumulation of secretions around the eye from affected Nox2 -KO SOD1 G93A transgenic mice suffering from infections (Supplemental Supplemental |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | accumulation of secretions around the eye from affected Nox2 -KO SOD1 G93A transgenic mice suffering from infections (Supplemental Supplemental Figure 6A |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | glands (the the Harderian gland and lacrimal gland of affected Nox2 -KO SOD1 G93A transgenic mice compared with Nox2 -WT SOD1 |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | the Harderian gland and lacrimal gland of affected Nox2 -KO SOD1 G93A transgenic mice compared with Nox2 -WT SOD1 G93A transgenic |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | of affected Nox2 -KO SOD1 G93A transgenic mice compared with Nox2 -WT SOD1 G93A transgenic mice ( n = 3 per |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | Nox2 -KO SOD1 G93A transgenic mice compared with Nox2 -WT SOD1 G93A transgenic mice ( n = 3 per group |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | First the Harderian gland of Nox2 -WT SOD1 G93A transgenic mice always contained accumulated porphyrin aggregates |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | First the Harderian gland of Nox2 -WT SOD1 G93A transgenic mice always contained accumulated porphyrin aggregates in the |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | lumen of glandular tubules that were never seen in affected Nox2 -KO SOD1 G93A transgenic mice (Supplemental Supplemental Figure 6 C |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | glandular tubules that were never seen in affected Nox2 -KO SOD1 G93A transgenic mice (Supplemental Supplemental Figure 6 C and F |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | possible that altered secretions from the Harderian gland of affected Nox2 -KO SOD1 G93A transgenic mice influence the observed increased predisposition |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | altered secretions from the Harderian gland of affected Nox2 -KO SOD1 G93A transgenic mice influence the observed increased predisposition to bacterial |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | architecture of the lacrimal glands were also observed in affected Nox2 -KO SOD1 G93A transgenic mice (Supplemental Supplemental Figure 6 D |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | the lacrimal glands were also observed in affected Nox2 -KO SOD1 G93A transgenic mice (Supplemental Supplemental Figure 6 D and G |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | may account for increased incidence of infection in eyes of Nox2 -KO SOD1 G93A transgenic mice |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | for increased incidence of infection in eyes of Nox2 -KO SOD1 G93A transgenic mice |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | It is presently unclear why overexpression of SOD1 G93A manifests these abnormalities only on the Nox2 -KO background |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | overexpression of SOD1 G93A manifests these abnormalities only on the Nox2 -KO background |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | However the findings imply potential new functions for both SOD1 and Nox2 in eye innate immunity |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | the findings imply potential new functions for both SOD1 and Nox2 in eye innate immunity |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | Compromised immune function in Nox2 -KO animals likely contributed to the lack of inflammation in |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | explain why the infection was only present in the ALS Nox2 -KO mice |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | microglia during the progression of ALS disease and that in Nox2 -KO mice there is a marked decrease in the number |
| 7889 | NOX1 | NADPH oxidase 1 | Nox1 | 4.2 | survival and delayed disease onset when 2 related Nox genes Nox1 and Nox2 were deleted |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | NOX2 | 7.1 | survival and delayed disease onset when 2 related Nox genes Nox1 and Nox2 were deleted |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | delayed disease onset when 2 related Nox genes Nox1 and Nox2 were deleted |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | Interestingly our findings in female SOD1 G93A transgenic mice heterozygous for the Nox2 X-linked gene and |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | findings in female SOD1 G93A transgenic mice heterozygous for the Nox2 X-linked gene and hence containing 50% Nox2-inactive cells suggest that |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | failed to find substantial protection against motor neuron defects in Nox2 -KO SOD1 G93A transgenic mice |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | find substantial protection against motor neuron defects in Nox2 -KO SOD1 G93A transgenic mice |
| 7889 | NOX1 | NADPH oxidase 1 | Nox1 | 4.2 | However the marginal increase in life span seen in the Nox1 -KO compared with the Nox2 -KO ALS mice would suggest |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | life span seen in the Nox1 -KO compared with the Nox2 -KO ALS mice would suggest that modifier genes must act |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | would suggest that modifier genes must act in concert with Nox2 deficiency to provide substantial improvements in survival |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | The potential existence of additional modifier genes that may influence Nox2 function in ALS would be particularly relevant to human ALS |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | reported as a consequence of disrupting a single gene ( Nox2 |
| 7889 | NOX1 | NADPH oxidase 1 | Nox1 | 4.2 | studies also demonstrate that more than 1 Nox gene ( Nox1 and Nox2 can influence disease progression in ALS mice |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | NOX2 | 7.1 | studies also demonstrate that more than 1 Nox gene ( Nox1 and Nox2 can influence disease progression in ALS mice |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | demonstrate that more than 1 Nox gene ( Nox1 and Nox2 can influence disease progression in ALS mice |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | in female ALS mice suggest that a 50% reduction in Nox2 activity can significantly alter the progression of disease in this |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | activity can significantly alter the progression of disease in this SOD1 G93A transgenic model of ALS |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD | 2.2 | used ALS amyotrophic lateral sclerosis CT threshold cycle HET heterozygous SOD superoxide dismutase |
| 7889 | NOX1 | NADPH oxidase 1 | Nox1 | 4.2 | Figure 1 Deletion of NADPH oxidase genes ( Nox1 or Nox2 enhances survival and survival index in ALS mice |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | Figure 1 Deletion of NADPH oxidase genes ( Nox1 or Nox2 enhances survival and survival index in ALS mice and significantly |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | and significantly reduces superoxide production in spinal cords of end-stage SOD1 G93A mice |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | Figure 2 Nox2 deficiency rescues motor neuron death in the spinal cords of |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | death in the spinal cords of mice hemizygous for the SOD1 G93A transgene |
| 2578 | CYBB | cytochrome b-245, beta polypeptide (chronic granulomatous disease) | Nox2 | 7.1 | Figure 3 Disease phenotyping of Nox2 genotypes on the SOD1 G93A ALS background |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 3.9 | Figure 3 Disease phenotyping of Nox2 genotypes on the SOD1 G93A ALS background |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | superoxide dismutase 1 | 1.0 | amyotrophic lateral sclerosis als is a fatal neurodegenerative disease that can be caused by dominant mutations in superoxide dismutase 1 sod1 1 . |
| 2577 | CYBA | cytochrome b-245, alpha polypeptide | p22 phox | 1.0 | nox1 and nox2 are closely related homologs in the nox gene family and share many of the same regulatory characteristics including a requirement for rac1 and p22 phox coactivators 10 _amp_#x02013; 12 . |
| 14874 | NOX5 | NADPH oxidase, EF-hand calcium binding domain 5 | nadph oxidase | 1.0 | here we show that disrupting either of these nadph oxidase genes nox1 or nox2 significantly delayed the progression of motor neuron disease in a sod1 g93a transgenic mouse model of als. |
| 14874 | NOX5 | NADPH oxidase, EF-hand calcium binding domain 5 | nadph oxidase | 1.0 | nadph oxidase activities were analyzed by measuring the rate of superoxide generation using a chemiluminescent lucigenin based system 27 with modification as previously described 28 . |
| 14874 | NOX5 | NADPH oxidase, EF-hand calcium binding domain 5 | nadph oxidase | 1.0 | the initial slope of the luminescence curve rlu/min was used to calculate the rate of luminescence product formation and compared between samples as an index of nadph oxidase activity. |
| 7661 | NCF2 | neutrophil cytosolic factor 2 (65kDa, chronic granulomatous disease, autosomal 2) | chronic granulomatous disease | 1.0 | however biased x chromosome inactivation has been previously reported in female patients with x linked chronic granulomatous disease caused by nox2 gene mutations 17 . |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | superoxide dismutase | 1.0 | footnotes nonstandard abbreviations used: als amyotrophic lateral sclerosis; ct threshold cycle; het heterozygous; sod superoxide dismutase. |
| 14874 | NOX5 | NADPH oxidase, EF-hand calcium binding domain 5 | nadph oxidase | 1.0 | figure 1 deletion of nadph oxidase genes nox1 or nox2 enhances survival and survival index in als mice and significantly reduces superoxide production in spinal cords of end stage sod1 g93a mice. |
| 7889 | NOX1 | NADPH oxidase 1 | nadph oxidase 1 | 1.0 | membrane glycoproteins|superoxide dismutase 1|superoxide dismutase|nadh nadph oxidoreductases|cybb protein mouse|nadph oxidase|nadph oxidase 1| |